Atara Biotherapeutics Inc  

(Public, NASDAQ:ATRA)   Watch this stock  
Find more results for John T. Isaacs, Ph.D.�
-0.05 (-0.21%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.77 - 24.22
52 week 13.31 - 59.41
Open 23.90
Vol / Avg. 211,179.00/279,600.00
Mkt cap 688.43M
P/E     -
Div/yield     -
EPS -2.37
Shares 28.74M
Beta     -
Inst. own 93%
Aug 4, 2016
Q2 2016 Atara Biotherapeutics Inc Earnings Release (Estimated) Add to calendar
Jun 21, 2016
Atara Biotherapeutics Inc at JMP Securities Life Sciences Conference
Jun 9, 2016
Atara Biotherapeutics Inc at Jefferies Healthcare Conference
Jun 7, 2016
Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference
May 5, 2016
Q1 2016 Atara Biotherapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -20.82% -26.55%
Return on average equity -21.46% -27.36%
Employees 55 -
CDP Score - -


611 Gateway Blvd Ste 900
United States - Map
+1-650-2788930 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

Officers and directors

Isaac E. Ciechanover M.D. President, Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
John F. McGrath Jr. Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Gad Soffer Chief Operating Officer
Age: 38
Bio & Compensation  - Reuters
Mitchall G. Clark Chief Regulatory and Quality Assurance Officer
Age: 54
Bio & Compensation  - Reuters
Christopher M. Haqq M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Carol Giltner Gallagher Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Eric L. Dobmeier Director
Age: 47
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
William K. Heiden Independent Director
Bio & Compensation  - Reuters
Joel S. Marcus J.D., CPA Independent Director
Age: 68
Bio & Compensation  - Reuters